Antibody-IL-2 fusion proteins: A novel strategy for immune potentiation

Human Antibodies

Volumn 8, Issue 3, 1997, Pages 106-118

  Penichet, Manuel L ^a   Harvill, Eric T ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody fusion protein; Cancer; Human IgG3; Interleukin 2; Interleukin 2 receptor; Treatment

Indexed keywords

ANTIBODY; CYTOKINE; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 2;

ANTIGEN BINDING; CANCER IMMUNOTHERAPY; CELL STIMULATION; COMPLEMENT ACTIVATION; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0030852457     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-1997-8301     Document Type: Review

References (92)

1. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologuous tumor by human lymphocytes cultured in T-cell growth factor. Cancer 1981; 41: 4420
2. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumor. J Immunol 1980: 125: 238
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. The lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823
4. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990; 50: 5234
5. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989; 49: 7086
6. Winkelhake JL, Gauny SS. Humn recombinant interleukin-2 as an experimental therapeutic. Pharm Rev 1990; 42: 1
7. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see comments]. JAMA 1994; 271: 907
8. Maas RA, Dullens HF, Den Otter W. Interleukin-2 cancer treatment: Disappointing or (still) promising?. A review. Cancer Immunol Immunother 1993; 36: 141
9. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694
10. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Safety 1992; 7: 417
11. Harada Y, Yahara I. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int Rev Exp Pathol 1993; 34: 37
12. Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J. Renal toxicity mediated by continuous infusion of recombinant interleukin-2. Nephron 1993; 64: 114
13. Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 1987; 47: 5725
14. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA. In vivo administration of purified human interleukin-2 half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135: 2865
15. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J. Immunol 1983; 130: 2203
16. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T, Neuwirt J. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations, preliminary report. Cancer Immunol Immunother 1983; 14: 205
17. Maas RA, Dullens HF, Dejong WH, Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 1989; 49: 7037
18. Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumor. Cancer Immunol Immunother 1991; 33: 389
19. Pizza G, Severini G, Menniti D, De Vinci C, Corrado F. Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Int J Cancer 1984; 34: 359
20. Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 1988; 62: 2482
21. Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, Den Otter W, Steerenberg PA, De Jong WH, Ruitenberg EJ. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma a pilot study. Cancer Immunol Immunother 1989; 30: 165
22. Su N, Ojeifo JO, MacPherson A, Zwiebel JA. Breast cancer gene therapy: Transgenic immunotherapy. Breast Cancer Res Treat 1994; 31: 349
23. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, Schaffner G, Birnstiel ML. Cancer vaccines: The interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711
24. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 1995. 154: 3406
25. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnstiel ML, Schweighoffer T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995; 92: 5540
26. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995; 58: 417
27. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522
28. McGrath JP, Cao XY, Schutz A, Lynch P, Coloma JM, Morrison SL, Putney SD. Bifunctional fusion between nerve growth factor and a transferring receptor antibody. J Neurosci Res 1997; 47: 123
29. Bebbington CR, Renner G, Thomson S, King G, Abrams D, Yarranton GT. High-level expression of a recombinant anti-body from myeloma cells using glutamine synthetase as an amplifiable selectable marker. Bio-Technology (NY) 1992; 10. 169
30. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988; 7: 1989
31. Tao MH, Morrison SL. Studies of aglycoylated chimeric mouse-human IgG- role of carbohydrate, the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143: 2595
32. Turner M. Molecules which recognize antigen. In: Roitt IM, Brostoff J, Male DK, eds. Immunology, 2nd Edn, London: Gower Medical Publishing, 1989
33. Shin SU, Friden P, Moran M, Morrison SL. Functional properties of antibody insulin-like growth factor fusion proteins. J Biol Chem 1994; 269: 4979
34. Harvill ET, Morrison SL. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1995; 1: 95
35. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 1986; 46: 3183
36. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumor. Cancer Res (Suppl.). 1990; 50: 814
37. Murray JL. Factors for improving monoclonal-antibody targeting. Diagn Oncol 1992; 2: 234
38. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993; 94: 297
39. Kemshead JT, Hopkins K. Uses and limiations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: A review. J R Soc Med 1993; 86: 219
40. Kosmas C, Linardou H, Epenetos AA. Advances in monoclonal antibody tumor targeting. J Drug Target 1993; 1: 81
41. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: Magic bullets or misguided missiles? Immunol Today 1993; 14: 252
42. Berinstein N, Levy R. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2. J Immunol 1987; 139: 971
43. Hank JA, Surfus J, Gah J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M, Wiersma S, Hammond D, Sondel PM. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994; 15: 29
44. Fell HP, Gayle MA, Grosmaire L, Ledbetter, JA. Genetic construction and characterization of a fusion protein consisting of a chimeric F (ab′) with specificity for carcinomas and human IL-2. J Immunol 1991; 146: 2446
45. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992; 89: 1428
46. Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 1993; 4: 230
47. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91: 9626
48. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994; 153: 4775
49. Hu P, Hornick JL, Glasky MS, Yun A, Milie MN, Khawli LA, Anderson PM, Epstein AL. A chimeric Lym-1/Interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 1996; 56: 4998
50. Harvill ET, Morrison SL. An IgG3-IL2 fusion protein has higher affinity than hrIL-2 for the IL-2 alpha subunit: Real time measurement of ligand binding. Mol Immunol 1996; 33: 1007
51. Harvill ET, Fleming JM, Morrison SL. In vivo properties of an IGG3-IL2 fusion protein: a general strategy for immune potentiation. J Immunol 1996; 157: 3165
52. Reithmüller G, Schneider-Gädicke E, Johnson JD. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5: 732
53. Tsomides TJ, Eisen HN. T-cell antigens in cancer. Proc Natl Acad Sci USA 1994; 91: 3487
54. Berinstein N, Starnes CO, Levy R. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 1988; 140: 2839
55. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL. Enhanced tumor uptake of macromolecules induced by a novel vasocative interleukin 2 immunoconjugate. Cancer Res 1991; 51: 2694
56. Hinuma S, Hazama M, Mayumi A, Fujisawa Y. A novel strategy for converting recombinant viral protein into high immunogenic antigen. FEBS Lett 1991; 288: 138
57. Hazama MA, Mayumi-Aono A, Asakawa N, Kuroda S, Hinuma S, Fujisawa Y. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 1993; 11: 629
58. Hazama MA, Mayumiaono A, Miyazaki T, Hinuma S, Fujisawa Y. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology 1993; 78: 643
59. Nakao M, Hazama M, Mayumi-Aono A, Hinuma S, Fujisawa Y. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. J Infect Dis 1994; 169: 787
60. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991; 173: 1483
61. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991; 173: 1025
62. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245
63. Zurawski SM, Vega F Jr, Doyle EL, Huyghe B, Flaherty K, McKay DB, Zurawski G. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J 1993;12: 5113
64. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332: 738
65. Tan LK, Shopes RJ, Oi VT, Morrison SL. Influence of the hinge region on complement activation, Clq binding, and segmental flexibility in chimeric human immunoglobulins [published erratum appears in Proc Natl Acad Sci USA 1991; 88: 5066]. Proc Natl Acad Sci USA 1990; 87: 162
66. Tao MH, Smith RI, Morrison SL. Structural features of human IgG which determine Isotype-specific differences in complement activation. J Exp Med 1993; 178: 661
67. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988; 332: 563
68. Chappel MS, Isenman DE, Everett M, Xu YY, Dorrington K, Klein MH. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci USA 1991; 88: 9036
69. Becker JC, Pancook JD, Gillies SD, Mendelsohn J. Reisfield RA. Erradicaiton of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion protein. Proc Natl Acad Sci USA 1996: 93: 2702
70. Bergman Y, Haimovich J, Melchers F. An IgM-producing tumor with biochemical characteristics of a small B lymphoctye. Eur J Immunol 1977; 7: 574
71. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977; 7: 413
72. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985; 4: 181
73. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 1986; 136: 1123
74. Carrasquillo JA, Bunn PA Jr, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Su MH, Gazdar AF, Mulshine JL, Oldham RK, Perentesis P, Horowitz M, Eddy J, James P, Larson SM. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med 1986; 315: 673
75. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28: 1358
76. Dykes PW, Bradwell AR, Chapman CE, Vaughan AT. Radioimmunotherapy of cancer: Clinical studies and limiting factors. Cancer Treat Rev 1987; 14: 87
77. Goldenberg DM. Targeting of cancer with radiolabeled antibodies. Prospects for imaging and therapy. Arch Pathol Lab Med 1988; 112: 580
78. Bischof Delaloye A, Delaloye B. Tumor imaging with monoclonal antibodies. Semin Nucl Med 1995; 25: 144
79. Fagerberg J, Frodin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascae in cancer patients treated with monclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to rnAb therapy? Cancer Immunol Immunother 1994; 38: 149
80. Burger UL, Chang MP, Goedegebuure PS, Eberlein TJ, Adams-Hodgins S. Recruitment of host CD8+T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer [published erratum appears in Surgery 1996; 119: 482]. Surgery. 1995; 117: 325
81. Durrant LG, Doran M, Austin EB, Robins RA. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int J Cancer 1995; 61: 62
82. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996; 93: 7826
83. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. Long-lived and -transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996; 98: 2801
84. Amigorena, SC, Bonnerot C, Fridman WH, Teillaud JL. Recombinant interleukin 2-activated natural killer cells regulate IgG2a production. Eur J Immunol 1990; 20: 1781
85. Murray HW, Welte K, Hacobs JL, Rubin BY, Mertelsmann R, Roberts RB. Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest 1985; 76: 1959
86. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, Polis MA, Walter RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane HC. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study [see comments]. N Engl J Med 1995; 332: 567
87. Prehn RH. Tumor immunogenicity: How far can it be pushed? Proc Natl Acad Sci USA 1993; 90: 4332
88. Prehn RH, Prehn LM. The flip side of tumor immunity. Arch Surg 1989; 124: 102
89. Prehn RH, Prehn LM. The autoimmune nature of cancer. Cancer Res 1987; 47: 927
90. Landolfi NF. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J Immunol 1991; 146: 915
91. Bogers WMJM, Lang F, Parker KE, LeMauff B, Anegon I, Jacques Y, Soulillou JP. Rat interleukin-2 immunoglobulin M fusion proteins are cytotoxic in vitro for cells expressing the IL-2 receipt and can abolish cell-mediated immunity in vivo. Transplantation 1994; 58: 932
92. Kunzendorf U, Pohl T, Bulfone-Paus S, Krause H, Notter M, Onu A, Walz G, Diamantstein T. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice. J Clin Invest 1996; 97: 1204